PharmaCyte Biotech, Inc.

NasdaqCM:PMCB Stock Report

Market Cap: US$8.2m

PharmaCyte Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for PharmaCyte Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Mar 22

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 07

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech (NASDAQ:PMCB) on Friday announced that its CEO Kenneth Waggoner had stepped down and said its board had authorized a business review committee to evaluate strategic opportunities for the company. Las Vegas, Nev. based PMCB is a biotech that is evaluating its live-cell encapsulation technology called Cell-in-a-Box for the potential development of therapies for cancer, diabetes and ascites, which is a condition in which fluid collects in the spaces within the abdomen. PMCB said its live-cell encapsulation technology involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. The company said it had appointed Joshua Silverman as interim CEO. The company also said it was assessing the concerns expressed by the U.S. FDA relating to the clinical hold placed on its investigational new drug application for the Cell-in-a-Box technology. PMCB stock +1.2% to $2.51 in early trading.
Seeking Alpha • Aug 15

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

PharmaCyte Biotech (NASDAQ:PMCB) said on Monday that it had signed a cooperation agreement with Iroquois Master Fund and its affiliates to includes two of Iroquois’ director designees to its Board of Directors. (PMCB) rose ~4% before the bell. Iroquois’ director designees, Jonathan Schechter and Joshua Silverman, will join PharmaCyte’s reconstituted Board as independent directors, the company said. "We are nearing the end of our process to fulfill the FDA’s requests to enable the clinical hold to be lifted. To date, approximately 90% of the FDA’s requests have been completed or are in process with one major pig study remaining to be completed," said PharmaCyte’s Chief Executive Officer, Kenneth Waggoner. Iroquois has agreed to certain customary standstill provisions and will support the Board’s full slate of directors at the 2022 Annual Meeting.
Seeking Alpha • Jan 07

Is This A Good Time To Invest In PharmaCyte?

PharmaCyte has developed a cell encapsulation technique that allows foreign cells to be injected into the body without triggering an immune response. The company is using their encapsulation technique as a basis for developing treatments for diabetes and cancer. Currently, the company has no income stream. Financing is entirely from the sale of corporate stock.
Seeking Alpha • Aug 21

PharmaCyte Biotech: Buy The 'Dump'

I recommend that you nibble a few shares of PharmaCyte Biotech if interested in a “trade” or a very high-risk long-term buy-and-hold. Historically, the company (or its investors) has proved to be quite expert in self-promotion. Your entry price per share should be at or below $4.25. The direct offering is for 14 million shares plus up to 7 million shares, through warrants, for minimum proceeds of $70 million. Gross proceeds from NASDAQ offering for $15 million plus the $70 million direct offering will be used for Phase 2b clinical trials.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PharmaCyte Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:PMCB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
1/31/2026N/A-7-5-5N/A
10/31/2025N/A-8-5-5N/A
7/31/2025N/A0-5-5N/A
4/30/2025N/A23-3-3N/A
1/31/2025N/A10-2-2N/A
10/31/2024N/A7-2-2N/A
7/31/2024N/A7-3-3N/A
4/30/2024N/A-17-2-2N/A
1/31/2024N/A-15-2-2N/A
10/31/2023N/A-10-2-2N/A
7/31/2023N/A-10-2-2N/A
4/30/2023N/A-4-4-4N/A
1/31/2023N/A-6-5-5N/A
10/31/2022N/A-6-4-4N/A
7/31/2022N/A-5-4-4N/A
4/30/2022N/A-4-4-4N/A
1/31/2022N/A-4-4-4N/A
10/31/2021N/A-4-4-4N/A
7/31/2021N/A-4-4-4N/A
4/30/2021N/A-4-3-3N/A
1/31/2021N/A-3-3-3N/A
10/31/2020N/A-3-3-3N/A
7/31/2020N/A-4-2-2N/A
4/30/2020N/A-4-2-2N/A
1/31/2020N/A-4-2-2N/A
10/31/2019N/A-4N/A-3N/A
7/31/2019N/A-4N/A-3N/A
4/30/2019N/A-4N/A-3N/A
1/31/2019N/A-4N/A-4N/A
10/31/2018N/A-6N/A-4N/A
7/31/2018N/A-6N/A-5N/A
4/30/2018N/A-7N/A-5N/A
1/31/2018N/A-7N/A-5N/A
10/31/2017N/A-6N/A-4N/A
7/31/2017N/A-5N/A-3N/A
4/30/2017N/A-4N/A-3N/A
1/31/2017N/A-4N/A-4N/A
10/31/2016N/A-5N/A-4N/A
7/31/2016N/A-6N/A-4N/A
4/30/2016N/A-6N/A-4N/A
1/31/2016N/A-8N/A-4N/A
10/31/2015N/A-7N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PMCB's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if PMCB's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if PMCB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PMCB's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PMCB's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PMCB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 15:30
End of Day Share Price 2026/05/19 00:00
Earnings2026/01/31
Annual Earnings2025/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaCyte Biotech, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WhiteH.C. Wainwright & Co.